Phillip P. Chan, Chief Executive Officer at Cytosorbents Corp (CTSO), bought 200,000 shares at $0.35 ($70K) on 2026-09-04, disclosed to the SEC on 2026-09-09.
CEO Phillip P. Chan purchased 200,000 shares for $70,000 at $0.35, signaling confidence in the stock's recovery potential following a steep 63.73% year-to-date decline.
The stock is trading at $0.362, down 7.39% over the last five days and 6.02% over the last 90 days, but remains 18.77% above its 52-week low of $0.3048.
Q2 2026 earnings on August 7, 2026, will be critical to validate the company's progress toward breakeven and its regulatory advances for DrugSorb-ATR.
The company faces significant execution risk regarding FDA approval for the DrugSorb-ATR device and potential setbacks in the STAR-T trial, as noted in recent earnings discussions.
Nothing distinguishes this filing.
| Filing → |
| CTSO | BUY | 2023-12-15 | $200K | — | Filing → |
| CTSO | BUY | 2022-12-09 | $7K | — | Filing → |
| CTSO | BUY | 2022-12-08 | $30K | — | Filing → |